All data are based on the daily closing price as of June 24, 2025
p

Pharmosa Biopharm

6875.TWO
1.74 USD
-0.04
-2.25%

Overview

Last close
1.74 usd
Market cap
203.65M usd
52 week high
3.83 usd
52 week low
1.52 usd
Target price
N/A usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
146.407
Price/Book Value
3.9547
Enterprise Value
183.99M usd
EV/Revenue
119.4535
EV/EBITDA
137.5667

Key financials

Revenue TTM
1.54M usd
Gross Profit TTM
409207.32 usd
EBITDA TTM
-9.53M usd
Earnings per Share
-0.07 usd
Dividend
N/A usd
Total assets
68.18M usd
Net debt
-49.92M usd

About

Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei City, Taiwan.
  • Symbol
    6875.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    Taipei City
  • Web site
    https://www.pharmosa.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top